,0
symbol,NBRV
price,0.45
beta,2.30972
volAvg,1665089
mktCap,67849200
lastDiv,0.0
range,0.386-2.11
changes,0.0271
companyName,Nabriva Therapeutics PLC
currency,USD
cik,0001641640
isin,IE00BYQMW233
cusip,G63637105
exchange,Nasdaq Global Select
exchangeShortName,NASDAQ
industry,Biotechnology
website,https://www.nabriva.com/
description,"Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development and commercialization of novel anti-infective agents to treat serious infections. The firm is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Companyâ€™s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin. Lefamulin is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. Lefamulin is being evaluated in two global, registrational Phase III clinical trials in patients with moderate to severe community-acquired bacterial pneumonia (CABP).It seeks to further pursue development of lefamulin for additional indications, including the treatment of acute bacterial skin and skin structure infections (ABSSSI), and is developing a formulation of lefamulin appropriate for pediatric use."
ceo,Mr. Theodore Schroeder
sector,Healthcare
country,IE
fullTimeEmployees,162
phone,6108166640
address,56 Fitzwilliam Square North
city,DUBLIN
state,
zip,1
dcfDiff,-2.87
dcf,0.0
image,https://financialmodelingprep.com/image-stock/NBRV.png
ipoDate,2015-09-18
defaultImage,False
